Health & Fitness
Fri, June 10, 2011Thu, June 9, 2011Wed, June 8, 2011Tue, June 7, 2011Mon, June 6, 2011Sat, June 4, 2011Fri, June 3, 2011Thu, June 2, 2011Wed, June 1, 2011Tue, May 31, 2011Mon, May 30, 2011Fri, May 27, 2011Thu, May 26, 2011Wed, May 25, 2011Tue, May 24, 2011Mon, May 23, 2011Sun, May 22, 2011Fri, May 20, 2011Thu, May 19, 2011Wed, May 18, 2011Tue, May 17, 2011Mon, May 16, 2011Sun, May 15, 2011Fri, May 13, 2011Thu, May 12, 2011Wed, May 11, 2011POZEN Ranked as Second Most Efficient Pharma Company by SmarTrend
Published in Health and Fitness on Wednesday, May 25th 2011 at 4:45 GMT by Market Wire
CHAPEL HILL, N.C.--([ BUSINESS WIRE ])--POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.
This evaluation was based on Revenue Per Employee (RPE) a" a measure used by analysts to compare the productivity of companies in the same industry a" and noted POZENa™s RPE as $2.28 million. The other companies included in the top-five list were Columbia Laboratories, Depomed, ViroPharma and Pain Therapeutics.
As a next-generation pharmaceutical company, POZENa™s philosophy is to own core capabilities and strategically partner for the rest. Its unique business model avoids some of the pitfalls of traditional drug development and commercialization, employing a small but expert team who lead the drug development strategy, partner selection and execution. The approach has delivered the approval of two self-invented products in two years a" something almost no other small pharmaceutical company has done.
About POZEN
POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained U.S. Food and Drug Administration approval of two self-invented products in two years a" something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN now is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its gastrointestinal toxicity. The lead candidate PA32540 is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol aPOZN.a For more detailed company information, including copies of this and other press releases, please visit [ www.pozen.com ].
